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Hedgehog pathway inhibitors (HPIs) are indi-
cated for locally advanced basal cell carcinoma
(laBCC) and metastatic basal cell carcinoma with
reported treatment length of 5.5months tomore than
5 years.1-3 The definition of laBCC is historically ill
described and only recently has a consensus defini-
tion been proposed.1,4 Treatment is indicated until
tumor resistance or adverse events cause interrup-
tion. Therefore, we do not know the length of
treatment necessary for tumor clearance. We
describe a patient who received a single 2-week
pulse treatment of HPI therapy and subsequently
experienced sustained clinical and histologic clear-
ance of his tumor.Fig 1. A Hispanic man presented with a large BCC, which
was previously treated with radiation. He was started on
vismodegib, but treatment abruptly ended after only
2 weeks.CASE REPORT
A medium-complected Hispanic man in his 50s
presentedwith a 6-month history of a laBCCon the left
eye. Fourteenmonths previously, the patient received
radiation therapy (RT), but the tumor recurred and
was now obstructing his vision. His history was
significant for smoking, working as handyman, and
family history of melanoma. Physical examination
found a 3.0- 3 2.7-cm vascular, friable, tumor on
his left lower eyelid with surrounding erythema,
ectropion, and injected conjunctiva (Fig 1). Two
biopsies found nodular basal cell carcinoma (BCC).
Consultation with the ophthalmic plastic surgery
department recommended orbital exenteration.
Imaging studies could not be performed because of
the patient’s uninsured and low-income status.
The patient was started on 150 mg vismodegib
daily. Treatment abruptly ended after 15 days whenthe Department of Dermatology and Cutaneous Surgery,
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m.the patient was incarcerated. Six weeks later, the
patient noted involution of the tumor. Twelve weeks
after treatment discontinuation, the patient had
complete clinical and histologic clearance confirmed
by biopsy. Sixteenmonths after his 2-week treatment
with vismodegib, he showed clinical and histologic
resolution as confirmed by repeat punch biopsy
(Fig 2).JAAD Case Reports 2016;2:360-1.
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Fig 2. Clearance of BCC after pulse vismodegib treatment.
The patient experienced persistent complete clinical and
histologic clearance of BCC 16 months after a 2-week
pulse with vismodegib.
Table I. Median duration of vismodegib exposure
and median time to response in the 3 largest
studies to date
Study Year
Number
of patients
in study
Median
duration of
vismodegib
exposure
Median time
to response
Basset-Seguin
et al6
2015 499 9.1 mo 2.7 mo
Chang et al5 2014 119 6.5 mo 2.6 mo
Sekulic et al2 2015 96 12.9 mo Not reported
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To our knowledge, no previously published study
has reported resolution of BCC with vismodegib
after such short treatment length. In the 3 largest
studies of vismodegib efficacy and safety to date,2,5,6
median duration of treatment has ranged from 6.5 to
12.9 months with the median time to response
approximately 2.5 months (Table I).
It appears that pharmacologic response to HPI
therapy is rapid. In a study of vismodegib for basal
cell nevus syndrome, patients had reduced hedge-
hog target gene expression and diminished tumor
cell proliferation after 1 month of treatment.7 Our
patient had complete sustained tumor resolution for
at least 14 months after 2 weeks of therapy. It is,therefore, likely that physiologic change also occurs
within a short timeframe. Response of BCC tumors to
HPI therapy is varied. It is possible that this variability
depends both on tumor and stromal characteristics.8
Significantly, our patient had received RT therapy
1 year earlier. The late changes of RT include
alterations of the dermis, and one possibility is
that stromal alteration rendered the tumor more
susceptible to the short course of HPI therapy.
However, scarring from RT may also make
tumor elimination more difficult. Several recently
published articles explore the use of HPI as an
adjuvant to surgery or radiation,1 although further
research is needed to determine the relative
response rates for laBCC after these combined
modalities.
The utility of vismodegib in treating basal cell
carcinoma has not been clearly defined. This
case highlights the need for further surveillance
of unusual clinical scenarios to help determine
appropriate uses.
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